Johnson & Johnson (NYSE:JNJ) Shares Sold by Coho Partners Ltd.

Coho Partners Ltd. decreased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 20.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 491,249 shares of the company's stock after selling 123,248 shares during the period. Johnson & Johnson accounts for 3.3% of Coho Partners Ltd.'s investment portfolio, making the stock its 13th largest holding. Coho Partners Ltd.'s holdings in Johnson & Johnson were worth $71,044,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. AMF Tjanstepension AB increased its position in Johnson & Johnson by 14.2% in the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company's stock valued at $68,985,000 after acquiring an additional 52,997 shares during the period. Alpha Financial Partners LLC acquired a new position in Johnson & Johnson during the third quarter worth $209,000. Wealth Group Ltd. acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth $213,000. Swedbank AB increased its holdings in Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company's stock valued at $358,980,000 after buying an additional 111,570 shares in the last quarter. Finally, Schaper Benz & Wise Investment Counsel Inc. WI increased its stake in Johnson & Johnson by 1.8% in the 3rd quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 97,483 shares of the company's stock valued at $15,798,000 after purchasing an additional 1,768 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research reports. Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Barclays raised their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research note on Tuesday, January 28th. Raymond James cut their price objective on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Wells Fargo & Company lowered their target price on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Finally, Guggenheim boosted their price target on Johnson & Johnson from $162.00 to $166.00 and gave the stock a "neutral" rating in a report on Monday, February 3rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $170.67.

Johnson & Johnson Trading Up 1.7 %

Shares of JNJ traded up $2.67 during mid-day trading on Friday, hitting $162.35. The company had a trading volume of 12,540,171 shares, compared to its average volume of 9,073,381. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The business's 50-day simple moving average is $148.93 and its 200-day simple moving average is $155.90. The stock has a market cap of $390.87 billion, a PE ratio of 24.41, a P/E/G ratio of 2.53 and a beta of 0.52. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the business earned $2.29 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.06%. Johnson & Johnson's dividend payout ratio is presently 74.59%.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.